Newsroom

Sorted by: Latest

-

Ecolab Delivers Strong Performance and Impact

ST. PAUL, Minn.--(BUSINESS WIRE)--The world is entering a period of historic growth, complexity and opportunity. As artificial intelligence reshapes industries and demand for energy, food and water accelerates, how companies grow next will matter as much as how fast they grow. In a rapidly changing world, Ecolab remains constant. Today, the company released its 2025 Growth & Impact Report highlighting how Ecolab continues to deliver strong business performance while deepening its impact on...
-

PeterMD and Lorient Partner to Accelerate Growth of the Nation’s First Fully Integrated Medicine 3.0 Platform

VERO BEACH, Fla.--(BUSINESS WIRE)--PeterMD and Lorient Partner to Accelerate Growth of the Nation’s First Fully Integrated Medicine 3.0 Platform...
-

Ralliant Reports First Quarter 2026 Results and Raises Full Year Guidance

RALEIGH, N.C.--(BUSINESS WIRE)--Ralliant Corporation (“Ralliant” or the “Company”) (NYSE: RAL) today announced financial results for the first quarter of 2026. For the first quarter, revenue of $535 million was up 11% year-over-year and up 9% organically year-over-year. Net earnings were $44 million, and adjusted net earnings were $65 million, resulting in EPS of $0.39 and adjusted EPS of $0.57. Net earnings margin was 8.3%, a 500 basis point decline year-over-year. Adjusted EBITDA margin was 1...
-

Sleep Number Announces First Quarter 2026 Results

MINNEAPOLIS--(BUSINESS WIRE)--Sleep Number Corporation (Nasdaq: SNBR) today reported results for the quarter ended April 4, 2026. Linda Findley, President and CEO, commented, “Q1 came in as expected given the soft start to the year, but year-over-year demand improved steadily throughout the quarter, ending with growth in March over last year. We are confident in the early positive metrics we are seeing from our new product launch and marketing campaigns, and the customer feedback on our new bed...
-

Veritone Reports First Quarter 2026 Results, Reaffirms 2026 Guide of $130-$145 million in Revenue in Fiscal 2026

IRVINE, Calif.--(BUSINESS WIRE)--Veritone, Inc. (NASDAQ: VERI) (“Veritone” or the “Company”), a leader in enterprise AI and data solutions, today announced results for the first quarter ended March 31, 2026. “During the first quarter, we accelerated the commercialization of Veritone Data Refinery, expanded public sector adoption, and further strengthened the foundation of our AI platform,” said Ryan Steelberg, President and Chief Executive Officer of Veritone. “With additional leading hyperscal...
-

GenNx360 Capital Partners Completes Sale of Precision Aviation Group to VSE Corporation for Approximately $2.025 Billion in Cash and Equity.

NEW YORK--(BUSINESS WIRE)--GenNx360 Capital Partners (“GenNx360”), a New York-based private equity firm, has announced the sale of its portfolio company, Precision Aviation Group, Inc. (“PAG” or the “Company”), to VSE Corporation (“VSE”) for a total upfront consideration of approximately $2.025 billion in cash and equity. Founded in 1996 and headquartered in Atlanta, Georgia, PAG is a best-in-class global provider of aviation maintenance, repair and overhaul (“MRO”) services, distribution and s...
-

Veterinary Dentistry Specialists® Opens New Practice in Philadelphia, PA

PHILADELPHIA--(BUSINESS WIRE)--Veterinary Dentistry Specialists® (VDS), a premier national network of specialty veterinary dentistry and oral surgery practices, is proud to announce the continued expansion of its advanced oral healthcare services. Located at 1710 Fairmount Avenue, in the heart of Philadelphia, VDS is unique in that board-certified veterinary specialists in dentistry and anesthesiology work together with each patient to ensure optimal care. This unique combination of expertise,...
-

Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address the underlying causes of psychiatric and neurological disorders, today announced that the first patient has been dosed in Ascend, its second Phase 3 study evaluating DT120 ODT (lysergide tartrate) for the treatment of major depressive disorder (MDD). The Ascend study will evaluate the...
-

AIRNA Presents New Preclinical Data on AATD Therapeutic Candidate AIR-001 and Cardiometabolic RNA-Editing Programs at ASGCT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--AIRNA, a biotech company pioneering RNA-editing therapeutics to transform the lives of patients with rare and common conditions, is presenting new preclinical data on its therapeutic candidate AIR-001 for the treatment of alpha-1 antitrypsin deficiency (AATD) and its cardiometabolic RNA-editing research programs at the 2026 Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in Boston from May 11-15, 2026. Together, the presentations demons...
-

Kraft Heinz Celebrates 250 Years of Summer Cookouts with “The United Tastes of America”

CHICAGO--(BUSINESS WIRE)--As America approaches its 250th anniversary, The Kraft Heinz Company is marking the moment the only way it knows how: by bringing people together over food. Today, as part of its America250 sponsorship, the company unveils “The United Tastes of America”, its largest portfolio campaign in history, celebrating the role its iconic brands have played in one of America’s favorite pastimes: summer cookouts. Coupled with never-before-seen products hitting grocery store shelve...